向仲怀 家蚕表型多样性示意图。 自膨胀蚕丝蛋白止血海绵。 家蚕基因和变异分布图。 蚕丝蛋白生物双面胶。 想象这样的场景：修复创伤时，用蚕丝蛋白制成的温和敷料，能加速愈合且不致敏；手术缝合线在体内 自然降解，无需拆线；甚至当眼角膜严重受损，一种蚕丝蛋白基的"人工角膜"能被快速移植，助患者重 见光明……这不是遥不可及的幻想，而是可以期待的未来。 作为自然材料，蚕丝蛋白能被人体安全地降解和吸收。因此，它在再生医学领域展现出很大的应用潜 力，并已被用于软骨、皮肤、角膜等损伤组织修复的研究。 向仲怀(左一)指导学生进行实验。 以上图片均为西南大学党委宣传部提供 网友：最近看到新闻报道，蚕丝不仅能做衣服，还能用来修复伤口，甚至制造"人工角膜"。一只小小的 蚕，原来有这么多神奇应用。这背后有什么科学原理？ 编辑：修复创伤时，使用蚕丝蛋白制成的温和敷料，能加速愈合且不致敏；眼角膜严重受损，一种蚕丝 蛋白基的"人工角膜"能被快速移植，助患者重见光明……这些应用场景其实并不遥远。本期"院士讲科 普"，我们邀请中国工程院院士、著名蚕学专家向仲怀，带大家了解现代科学视野中的家蚕。 蚕丝蛋白：极具想象力的"智慧材料" 蚕丝，质地轻盈、 ...

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" innovation track [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven new medical aesthetic product development [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Technological Advancements - The collaboration aims to create a "dry-wet closed-loop" R&D platform that integrates AI design, high-throughput experimental validation, and data feedback iteration, enhancing the value of the medical aesthetics business [2] - The use of advanced generative models and large language models will shorten the early-stage R&D molecular screening cycle, reduce development costs, and improve the success rate of R&D in the medical aesthetics field [2] Group 3: Market Positioning - The focus on high-end medical aesthetic raw material innovation aims to break the dependency on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetic products towards "high-end and domestically produced" [1] - The collaboration is expected to address unmet market needs in the medical aesthetics sector, injecting momentum into the long-term development of Four Seasons' medical aesthetics business and enhancing its core competitiveness and market value [2]